单位：[1]Department of Clinical laboratory, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.[2]Department of Information Center, China-Japan Friendship Hospital, 100029 Beijing, China.[3]Department of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.[4]Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, 510260 Guangzhou, China.[5]Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, The Second Affiliated Hospital of Guangzhou Medical University, 510260 Guangzhou, China.[6]Translational Medicine Center, Huaihe Hospital of Henan University, 475000 Kaifeng, China.[7]Department of Hematology, Huaihe Hospital of Henan University, 475000 Kaifeng, China.[8]Department of Hematology, Institute of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, 510630 Guangzhou, China.中山大学附属第三医院
Multiple myeloma (MM) is a hematologic tumor with monoclonal proliferation of malignant plasma cells in the bone marrow. Fascin (FSCN) is an actin-binding protein that plays a crucial role in cell migration and invasion, contributing to tumor metastasis. There are three members (FSCN1-3) in FSCN family. However, the prognostic role of FSCN family in MM remains unclear. In this study, we used four independent Gene Expression Omnibus (GEO) datasets to explore the relationships between FSCN1-3 expression profiles and patient survival in MM. We found that FSCN1 was dramatically down-regulated in MM compared to normal donors (p < 0.001) and monoclonal gammopathy of undetermined significance (MGUS) (p = 0.032). Patients with high expression of FSCN1 and FSCN2 had significantly longer OS (p = 0.023 and 0.028, respectively). Univariate and multivariate analysis showed that FSCN1 (p = 0.003, 0.002) and FSCN2 (p = 0.018, 0.013) were independent favorable prognostic factors for OS in MM. Moreover, the combination of high expression of FSCN1 and FSCN2 could effectively predict both longer EFS (p = 0.046) and OS (p = 0.015). Our study suggested that FSCN1 and FSCN2 can be used as favorable biomarkers for predicting clinical outcomes in MM.
基金：
Medical Scientific Research Foundation of Guangdong Province, China [A2019472, A2018031]; Xinjiang Joint Fund of National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U1903117]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81500118, 81970193]; Guangdong Basic and Applied Basic Research Foundation [2019A1515011327]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [19ykpy39]
第一作者单位：[1]Department of Clinical laboratory, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
共同第一作者：
通讯作者：
通讯机构：[3]Department of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.[4]Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, 510260 Guangzhou, China.[5]Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, The Second Affiliated Hospital of Guangzhou Medical University, 510260 Guangzhou, China.[6]Translational Medicine Center, Huaihe Hospital of Henan University, 475000 Kaifeng, China.[7]Department of Hematology, Huaihe Hospital of Henan University, 475000 Kaifeng, China.
推荐引用方式(GB/T 7714)：
Deng Cong,Si Chaozeng,Ye Xu,et al.Prognostic significance of FSCN family in multiple myeloma[J].JOURNAL of CANCER.2021,12(7):1936-1944.doi:10.7150/jca.53675.
APA：
Deng, Cong,Si, Chaozeng,Ye, Xu,Zhou, Qiang,Zeng, Tiansheng...&Qian, Tingting.(2021).Prognostic significance of FSCN family in multiple myeloma.JOURNAL of CANCER,12,(7)
MLA：
Deng, Cong,et al."Prognostic significance of FSCN family in multiple myeloma".JOURNAL of CANCER 12..7(2021):1936-1944
